Rexulti expiry date?

When does Rexulti (brexpiprazole) patent/exclusivity end?

DrugPatentWatch.com tracks patent and exclusivity timelines for branded medicines. Checking Rexulti on DrugPatentWatch is the fastest way to see the latest “expiry date” information tied to specific patents and regulatory exclusivities. You can view the Rexulti page here: DrugPatentWatch – Rexulti (brexpiprazole).

Which “expiry date” do people mean: patent expiry, exclusivity, or both?

“Expiry date” can mean different things, and they often don’t line up:
- Patent expiry: When relevant listed patents are no longer enforceable, depending on litigation and whether any additional patents remain in force.
- Regulatory exclusivity (brand-only periods): Time during which the FDA may limit approval of generic/biosimilar versions even if patents have not fully run out.
DrugPatentWatch’s listing typically breaks out these categories so you can tell which date applies to your question. [1]

What happens if a generic company files before Rexulti’s expiry?

If a generic/biosimilar applicant files an application that seeks FDA approval before the relevant expiry dates, the FDA decision can still be blocked or delayed by unexpired patents and/or exclusivity periods, and by related patent litigation. The exact outcome depends on which patents are asserted and whether they expire first. DrugPatentWatch is useful for identifying which patents are associated with the product and their expected timelines. [1]

How can I verify the specific Rexulti expiry date for my use case?

To get the most accurate answer, note:
- The country (U.S. vs other markets) because exclusivity and patent landscapes differ.
- Whether you mean “first generic entry,” “full patent expiry,” or “last exclusivity date.”
DrugPatentWatch is designed to help map those distinctions for each drug. [1]

Sources:
1. DrugPatentWatch – Rexulti (brexpiprazole)